Forecast

There is no analyst data available for this company.

News Go to news feed

FutureGen Industries reports quarterly loss of CAD 0.06 per share

FutureGen Industries reported a loss per share of CAD 0.06 for the quarter ended March 31, 2026. In the same quarter a year earlier the company had posted a profit of CAD 0.03 per share. No information on revenue or causes was disclosed. » More on finanzen.net
FutureGen Industries reports increase in earnings per share in quarter ended December 31, 2025

FutureGen Industries reported earnings per share of CAD 0.02 for the quarter ended December 31, 2025. In the year-ago quarter, earnings per share were -CAD 0.010. » More on finanzen.net
FutureGen Industries realizes large portfolio gains from several biotech and life‑sciences holdings

FutureGen Industries reports significant realized gains in 2025 from sales of stakes in Onco-Innovations, ASEP Medical Holdings and Core One Labs. The disposals generated proceeds of several hundred thousand US dollars, with Onco-Innovations notably delivering a 9,816% return; ASEP and Core One also produced double- to four-digit returns. The company emphasizes its disciplined investment approach and focus on early-stage stakes in biotech, AI, robotics, quantum and defense to create sustainable shareholder value. » More on finanzen.net

In the last quarter, FutureGen Industries had revenue of 0,00€ and net profit of −1,96M€